Skip to Main Content

Good morning, everyone, and how are you today? A bright, shiny sun is illuminating the windswept Pharmalot campus, where the short person has left for the local schoolhouse and Mrs. Pharmalot is off to a new endeavor. As for us, we are engrossed in the usual routine of sniffing around for interesting items. A few tidbits, meanwhile, appear below. Time to hoist our cup of stimulation in celebration of another eventful day. Hope yours goes well …

Sanofi hired a leading AstraZeneca scientist, Yong-Jun Liu, as its new research head, the second high-profile researcher to leave the drug maker in the past year. Liu, who is a specialist in immunology, currently heads the MedImmune biotech unit at AstraZeneca, where he has worked since 2014. At Sanofi, which is undergoing a reorganization, he will head research and report to Elias Zerhouni, who oversees global R&D.

Doctors in New York are now required to send prescriptions to pharmacies electronically instead of handing patients a handwritten prescription slip, CBS News reports. The move is intended to combat the ongoing abuse and misuse of opioid painkillers. About 60 percent of prescriptions are now sent electronically, although the trend is still largely voluntary.


A study published Monday showed that Theranos’s results for total cholesterol were lower by an average of 9.3 percent than those from Quest and LabCorp, the two largest labs in the US, and could alter medical decisions made by physicians, The Wall Street Journal reports. Doctors use these lab tests to help determine when to prescribe statins, which are used to lower cholesterol.

Novo Nordisk broke ground Monday on a new $1.8 billion manufacturing facility in Clayton, N.C., which is forecast to add nearly 700 jobs to the area, The Triangle Business Journal writes.


Drug makers told an Indian court that a government’s decision to ban 344 fixed-drug combinations was made without considering any clinical data, The Economic Times tells us.

A federal appeals court upheld a verdict in favor of Pfizer against a man who claimed he developed a potentially fatal lung condition from Pondimin, once one-half of the “fen-phen” diet treatment, Reuters reports.

Natco Pharma stock nosedived after the company received 483 observations from the US Food and Drug Administration concerning two facilities in India, The Economic Times writes.

Advanced BioHealing executive Todd Clawson pleaded guilty last week to a charges of paying kickbacks to Veterans Affairs doctors for promoting a company product, The Seattle Post-Intelligencer informs us.

Chase Pharmaceuticals, which recently hired former Allergan president Doug Ingram as its chief executive, has raised $12 million in a new equity round, MedCity News says.